Skip to main navigation Skip to search Skip to main content

Phase 2 multicenter, randomized, double-blind, placebo-controlled, multiple dosing interval, 3-period studyof the safety, tolerability and effectiveness of adoptively transferred Viralym-M multivirus-specific T cells inkidney transplant recipients w

Project: Research project

Project Details

Description

Phase 2 multicenter, randomized, double-blind, placebo-controlled, multiple dosing interval, 3-period study of the safety, tolerability and effectiveness of adoptively transferred Viralym-M multivirus-specific T cells in kidney transplant recipients w
StatusFinished
Effective start/end date4/28/21 → 11/30/25

Funding

  • ALLOVIR, INC

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
View full fingerprint